These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27023789)

  • 1. Brexpiprazole: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexpiprazole: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.
    Ishigooka J; Iwashita S; Higashi K; Liew EL; Tadori Y
    J Clin Pharmacol; 2018 Jan; 58(1):74-80. PubMed ID: 28750151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
    Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
    Correll CU; Shi L; Weiss C; Hobart M; Eramo A; Duffy RA; Weiller E; Baker RA
    CNS Spectr; 2019 Oct; 24(5):507-517. PubMed ID: 30306884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Jun; 72(6):445-453. PubMed ID: 29582518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexpiprazole: First Global Approval.
    Greig SL
    Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive brexpiprazole for the treatment of major depressive disorder.
    Beyer JL; Weisler RH
    Expert Opin Pharmacother; 2016 Dec; 17(17):2331-2339. PubMed ID: 27788337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.
    McKeage K
    CNS Drugs; 2016 Feb; 30(2):91-9. PubMed ID: 26849053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
    Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists.
    Bieńkowski P; Wichniak A
    Psychiatr Pol; 2024 Apr; 58(2):237-248. PubMed ID: 39003508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
    Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
    Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.